Neuphoria TherapeuticsNEUP
13F holders, Q1 2026 (March 31)19holders −2
4new positions
7sold out
1famous investor
$4.07avg. 13F price*
At the end of Q1 2026, 19 institutions reported holding Neuphoria Therapeutics Inc. (NEUP) in their 13F filings, down 2 from Q4 2025. 4 opened new positions and 7 sold out. The largest holders were Lynx1 Capital Management LP ($3.6M), AdvisorShares Investments LLC ($632K) and Shay Capital LLC ($615K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Neuphoria Therapeutics Inc.
- CUSIP
- 64136E102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $1.0M |
| Exits | 7 | $420K |
All 13F filers, Q4 2025 → Q1 2026: 306,931 shares bought and 126,225 shares sold, net +180,706 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| Lynx1 Capital Management LP | 0.56% | Add +0.0% | 875,328 | $3.6M |
| AdvisorShares Investments LLC | 0.12% | Add +15.8% | 155,367 | $632K |
| Shay Capital LLC | 0.09% | Reduce -10.7% | 151,010 | $615K |
| Balyasny Asset Management L.P. | 0.00% | New | 142,183 | $579K |
| Vanguard Capital Management LLC | 0.00% | — | 98,516 | $401K |
| Squadron Capital Management LLC | 0.12% | New | 76,728 | $312K |
| Geode Capital Management, LLC | 0.00% | Add +200.6% | 52,007 | $212K |
| Ikarian Capital, LLC | 0.03% | No change | 47,443 | $193K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 33,589 | $137K |
| ADAR1 Capital Management, LLC | 0.01% | No change | 30,000 | $122K |
| FNY Investment Advisers, LLC | 0.05% | No change | 26,500 | $107K |
| Citadel Advisors | 0.00% | New | 19,331 | $79K |
| Boothbay Fund Management, LLC | 0.00% | No change | 14,000 | $57K |
| Virtu Financial LLC | 0.00% | New | 12,033 | $49K |
| Commonwealth Equity Services, LLC | 0.00% | Add +0.1% | 11,222 | $46K |
| Merck & Co., Inc. | 0.01% | No change | 10,027 | $41K |
| UBS Group AG | 0.00% | Add +40.2% | 2,316 | $9K |
| Rhumbline Advisers | 0.00% | No change | 202 | $822 |
| Morgan Stanley | 0.00% | No change | 58 | $236 |
"% of holder's portfolio" is NEUP's weight in each manager's 13F, not the share of Neuphoria Therapeutics Inc. the manager owns.